



SHUKRA
PHARMACEUTICALS LTD.

Date: January 4, 2025

To,
The Dy. Gen Manager
Corporate Relationship Dept.
BSE Limited
P.J. Tower, Dalal Street,
Mumbai- 400 001.

Scrip Code: 524632

Subject: Intimation pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/Madam,

This is in continuation to our earlier intimations dated November 29, 2024, approving the offer and issue of equity shares of the Company by way of a rights issue to eligible shareholders of the Company as on the record date (to be decided at a later date) for an amount not exceeding ₹ 36 crore in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws (the "Rights Issue").

Please note that a meeting of the Right Issue Committee of the Board ("Committee") is scheduled to be held on Thursday, January 9, 2025 inter alia, to consider, discuss and decide on various matters in connection with the Rights Issue including the specific terms such as the determination of the rights issue price and related payment mechanism, rights entitlement ratio, the record date, timing of the rights issue and other related matters.

We request you to take the above on record.

Thanking you,

Yours faithfully

For, Shukra Pharmaceuticals Limited

(Bhoomiben Patel)
Director
DIN: 08316893



CIN : L24231GJ1993PLC019079